# Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/diabetes-mellitus-efficacy-endpoints-for-clinical-trials-investigating-antidiabetic-drugs-and-biological-products/b83095c6-9f4a-4d0e-bbb2-0e2c8a11e2f1

> FDA guidance document: Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products. Issue date: May 25, 2023. Get complete insights and analysis.

---

## Details

- Title: Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-05-25
- Comment Close Date: 2023-08-24
- Last Changed: 2024-04-11
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-0625">FDA-2023-D-0625</a>

## Related Documents

- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Mpox: Development of Drugs and Biological Products; Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/mpox-development-of-drugs-and-biological-products-guidance-for-industry/ef1c9a82-c229-49ef-a357-d9947fb4dcdb)
- [General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological-products/764daa65-55f6-4702-b131-6e18ebf48434)